Viking Therapeutics, Inc. (VKTX)
26.17
-0.71
(-2.64%)
USD |
NASDAQ |
Nov 18, 16:00
26.39
+0.22
(+0.84%)
After-Hours: 07:36
Viking Therapeutics Enterprise Value : 2.632B for Nov. 18, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 18, 2026 | 2.632B |
| November 17, 2026 | 2.723B |
| November 16, 2026 | 2.712B |
| November 13, 2026 | 3.021B |
| November 12, 2026 | 2.812B |
| November 11, 2026 | 2.922B |
| November 10, 2026 | 2.950B |
| November 09, 2026 | 2.992B |
| November 06, 2026 | 2.718B |
| November 05, 2026 | 2.584B |
| November 04, 2026 | 2.862B |
| November 03, 2026 | 2.622B |
| November 02, 2026 | 2.716B |
| October 30, 2026 | 2.774B |
| October 29, 2026 | 2.720B |
| October 28, 2026 | 2.529B |
| October 27, 2026 | 2.469B |
| October 26, 2026 | 2.382B |
| October 23, 2026 | 2.406B |
| October 22, 2026 | 2.589B |
| October 21, 2026 | 2.659B |
| October 20, 2026 | 2.701B |
| October 19, 2026 | 2.489B |
| October 16, 2026 | 2.505B |
| October 15, 2026 | 2.785B |
| Date | Value |
|---|---|
| October 14, 2026 | 2.543B |
| October 13, 2026 | 2.693B |
| October 12, 2026 | 2.909B |
| October 09, 2026 | 2.931B |
| October 08, 2026 | 2.831B |
| October 07, 2026 | 2.934B |
| October 06, 2026 | 2.914B |
| October 05, 2026 | 3.029B |
| October 02, 2026 | 3.113B |
| October 01, 2026 | 3.186B |
| September 30, 2026 | 3.452B |
| September 29, 2026 | 3.213B |
| September 28, 2026 | 3.355B |
| September 25, 2026 | 3.651B |
| September 24, 2026 | 3.789B |
| September 23, 2026 | 4.361B |
| September 22, 2026 | 4.268B |
| September 21, 2026 | 3.015B |
| September 18, 2026 | 2.884B |
| September 17, 2026 | 2.927B |
| September 16, 2026 | 2.946B |
| September 15, 2026 | 2.996B |
| September 14, 2026 | 3.180B |
| September 11, 2026 | 3.233B |
| September 10, 2026 | 3.250B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Eli Lilly & Co. | 1.346T |
| Ironwood Pharmaceuticals, Inc. | 1.041B |
| Compass Therapeutics, Inc. | -43.79M |
| Amgen, Inc. | 280.92B |
| ACADIA Pharmaceuticals, Inc. | 2.176B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -183.19M |
| Total Expenses (Quarterly) | 183.19M |
| EPS Diluted (Quarterly) | -1.552 |
| Earnings Yield | -20.66% |
| Normalized Earnings Yield | -20.66 |